|
gptkbp:instanceOf
|
antineoplastic agent
platinum-based antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
1989
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XA02
|
|
gptkbp:brand
|
gptkb:Paraplatin
|
|
gptkbp:CASNumber
|
41575-94-4
|
|
gptkbp:category
|
antineoplastic agent
DNA synthesis inhibitor
platinum compound
|
|
gptkbp:chemicalFormula
|
C6H12N2O4Pt
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
hypersensitivity to platinum compounds
severe myelosuppression
|
|
gptkbp:developed_to_reduce
|
nephrotoxicity compared to cisplatin
|
|
gptkbp:discoveredBy
|
gptkb:John_F._Kennedy_Institute,_Denmark
|
|
gptkbp:eliminationHalfLife
|
1.5–6 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1980s
|
|
gptkbp:form
|
powder for solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
carboplatin
|
|
gptkbp:KEGGID
|
D00217
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA crosslinking
|
|
gptkbp:MeSH_ID
|
D015313
|
|
gptkbp:metabolism
|
non-enzymatic
|
|
gptkbp:molecularWeight
|
371.25 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL1377
5311293
DB00958
|
|
gptkbp:relatedTo
|
gptkb:cisplatin
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
nephrotoxicity
allergic reactions
ototoxicity
myelosuppression
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:synonym
|
gptkb:CBDCA
cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)
|
|
gptkbp:UNII
|
Q1K0A10Z02
|
|
gptkbp:usedFor
|
gptkb:cancer
testicular cancer
head and neck cancer
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
|
|
gptkbp:bfsLayer
|
6
|